Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obrindatamab + retifanlimab in B7-H3-expressing tumors
NCT03406949Phase 1Completed
- Sponsor
- MacroGenics
- Start
- Feb 2018
- Primary completion
- Apr 2022
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of obrindatamab in solid tumor (advanced stage), sponsored by MacroGenics. Primary endpoints: Treatment-Emergent Adverse Events at 30 months and Maximum Tolerated Dose / Maximum Administered Dose at 18 months. Started Feb 2018; status: completed.
02
Drugs
obrindatamab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03406949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03406949.